Recruiting

Observational Study

Sponsor:

Cedars-Sinai Medical Center

Code:

NCT06988150

Conditions

Pancreatic Adenocarcinoma

Weight Loss

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status. Each patient will be tested for SIBO using Lactulose Hydrogen Breath Test. 100 patients with diagnosed pancreatic adenocarcinoma and clinically diagnosed weight loss will be enrolled in this study.

Conditions

Pancreatic Adenocarcinoma

Weight Loss

Study ID

NCT06988150

Start date

Apr 14, 2025

Status verified date

Oct, 2026

Completion date

Oct 14, 2028

Anticipated

Primary completion date

Oct 14, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Men, Women, and all genders
  • Individuals 18 years old or older are included.
  • Patients of the study investigators and team members
  • Diagnosis of pancreatic ductal adenocarcinoma
  • All subjects must consent to this study
  • Clinically diagnosed weight loss

Exclusion Criteria:

  • Minors
  • Pregnant Women
  • Any records flagged "break the glass" or "research opt out."
  • Patients who have received treatment for SIBO in the past 3 months

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Arms

Pancreatic adenocarcinoma with clinically significant weight loss.

Patients diagnosed with pancreatic adenocarcinoma with clinically significant weight loss.

Primary outcome measure

  • SIBO in PDAC [ Time Frame: At Screening Visit ]

Central Contacts and Locations

Central contacts

Clinical Trials Navigator

310-423-2133GroupCancerTrialInformation@cshs.org

Locations

Cedars-Sinai Medical Center

Recruiting

Los Angeles, California, United States, 90048

Contacts

Abrahm Levi

310-248-8084abrahm.levi@cshs.org

Principal Investigator:

Andrew E. Hendifar, M.D., M.P.H.

More Information

Sponsor

Cedars-Sinai Medical Center

Last update posted

Oct 20, 2026

Last verified

Oct, 2026

Keywords

  • PDAC

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-24. This information was provided to ClinicalTrials.gov by Cedars-Sinai Medical Center on 2026-10-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.